Novel therapeutic modalities in pediatric inflammatory bowel disease.
Management of inflammatory bowel disease in childhood poses great challenges. Apart from the disease complications, the drugs' adverse affects, especially corticosteroids, are significant. In the past decade major progress was made in elucidating the pathogenesis of IBD, which led to new treatment options aiming to achieve better control of the disease and decrease the various complications of current therapy. In this review we provide an overview of novel therapies for IBD, their efficacy, safety and their current use in children.
Shteyer
Eyal
E
Pediatric Gastroenterology Unit, Hadassah-Hebrew University Hospitals, Jerusalem, Israel. eyals@hadassah.org.il
Wilschanski
Michael
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000378:metabolism; D039441:Integrin alpha4; D009173:Mycophenolic Acid / Q000627:therapeutic use; D000069442:Natalizumab; D019936:Probiotics / Q000627:therapeutic use; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; C501380:MLN02 antibody, human; D000069442:Natalizumab; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D039441:Integrin alpha4; C505731:fontolizumab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077552:Basiliximab; D009173:Mycophenolic Acid; D016559:Tacrolimus